Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 353 - 360 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC2233 | SMI-4a |
|
Selective, ATP-competitive Pim kinase inhibitor (IC<sub>50</sub> values are 24 and 100 nM for Pim-1 and Pim-2 respectively). Displays selectivity over a panel of ~50 other kinases tested. Exhibits cytotoxicity in PC3 prostate carcinoma cells <em>in vitro</em> (IC<sub>50</sub> = 17 <span class='symbol'>μ</span>M).
|
|
| BCC2238 | RITA (NSC 652287) |
|
Anti-tumor agent that binds wild-type p53 (Kd = 1.5 nM) preventing p53-MDM2 (HDM2) interaction. Induces p53 accumulation and stimulates apoptosis in tumor cell lines expressing wild-type p53 in vitro and in vivo. Inhibits HPV-E6-mediated proteasomal degradation. Suppresses expression of cervical carcinoma HeLa xenografts in vivo.
|
|
| BCC2239 | Tenovin-1 |
|
p53 activator that protects against MDM2-mediated p53 degradation. Elevates levels of p53 and p21<sup>CIP/WAF1</sup> and induces expression from an endogenous p53-dependent promoter. Exhibits potent antiproliferative activity <em>in vitro</em>.
|
|
| BCC2241 | Pifithrin-α (PFTα) |
|
Inhibitor of p53; reversibly blocks p53-dependent transcriptional activation and apoptosis. Protects against neuronal death in models of stroke and neurodegenerative disorders. Active <em>in vivo</em>; protects mice from the side-effects of cancer therapy associated with p53 induction. Supresses self-renewal of embryonic stem cells. Also aryl hydrocarbon receptor (AHR) agonist, causes upregulation of AHR target gene CYP1A1 (EC<sub>50</sub> = 1.1 <span class='symbol'>μ</span>M). Cyclic analog available.
|
|
| BCC2242 | NSC 319726 |
|
Reactivator of mutant p53. Restores wild type p53 structure and function to the p53R175 mutant. Inhibits growth of fibroblasts expressing the p53R175 mutation (IC50 = 8 nM). Also inhibits growth of xenograft tumors expressing the p53R175 mutation in vivo.
|
|
| BCC2244 | Bay 11-7821(BAY 11-7082) |
|
E2 ubiquitin (Ub) conjugating enzyme inhibitor. Inhibits the conjugation of Ub to a range of E2 enzymes. Inhibits E2 enzyme mediated I<span class='symbol'>κ</span>B<span class='symbol'>α</span> phosphorylation and indirectly decreases NF-<span class='symbol'>κ</span>b activity. Also reversibly activates MAPK signaling. Induces apoptosis of leukemic T cell and B-cell lymphoma cell lines.
|
|
| BCC2247 | Necrostatin-1 |
|
ATP-competitive, allosteric inhibitor of receptor-interacting protein kinase 1 (RIPK1) (EC50 = 182 nM). Blocks non-apoptotic cell death via inhibition of a specific cellular pathway, necroptosis, which leads to necrosis (EC50 = 494 nM). Reduces ischemic brain injury in a mouse model of stroke.
|
|
| BCC2248 | Thalidomide |
|
Teratogen, sedative-hypnotic with inherent anti-inflammatory properties. A selective inhibitor of tumor necrosis factor <span class='symbol'>α</span> (TNF-<span class='symbol'>α</span>) synthesis.
|
|